February 27, 2016

Earlier this week Lyxumia (generic name Lixisenatide), a new drug that helps to control type II diabetes, was launched in the UK. In addition to being an effective and saft therapy for type II diabeted, including in some patients that do not respond to current first-line therapies, Lyxumia is relatively inexpensive when compared to current therapies for type II diabetes, which will help to save the health services money that can be invested in other therapies.

Lyxumia belongs to a new class of drugs known as the glucagon-like peptide 1 receptor agonists that work by increasing the secretion of insulin in response to consumption of food, and is administered by a once daily injection.That animal research played a key role in the development of the glucagon-like peptide 1 (GLP-1) receptor agonists for treating diabetes should not be a surprise, but when I took a quick look at the paper (1) reporting the preclinical development of Lyxumia (them called ZP10A)  I got a surprise.


Tapp here to learn more about this development in type 2 diabetes treatment.

Heard of this story? Comment here with your expertise.

TAPP to read more.

Please contact content@tappnetwork.com with any DMCA or other intellectual property concerns.